China NMPA Drug Inspection - Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. - Stir-fried Atractylodes lancea

On October 13, 2017, the Henan Provincial Food and Drug Administration issued an announcement regarding four batches of substandard traditional Chinese medicine products, identified during inspections conducted by various local drug inspection agencies. Three pharmaceutical companies were implicated: Anhui Youxin Pharmaceutical Co., Ltd., Anhui Zehua Guoyao Pieces Co., Ltd., and Xuchang Tiantiankang Pharmacy Co., Ltd. Xuji Avenue Store. Anhui Youxin Pharmaceutical Co., Ltd. was found to have two batches of substandard products: Banlangen (batch 160301) failed due to excessive sulfur dioxide residue, and Haijinsha (batch 161201) was non-compliant due to its total ash content. Anhui Zehua Guoyao Pieces Co., Ltd.'s Chao Cangzhu (batch 160801) was deemed substandard based on its content. Additionally, Gou Teng, sourced from Xuchang Tiantiankang Pharmacy Co., Ltd. Xuji Avenue Store, failed quality standards due to its appearance. Operating under the oversight of the Henan Provincial Food and Drug Administration, which functions within the broader regulatory framework of the National Medical Products Administration (NMPA), immediate actions were mandated. Regulatory departments were instructed to implement control measures, including the sealing, seizure, and suspension of sales for the identified substandard drugs. Furthermore, investigations and legal penalties against the responsible manufacturing and sourcing units were initiated to ensure compliance with drug safety regulations.